Anderson-Fabry disease fitness improvement program

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants with Fabry disease are assigned to either a supervised 12-week exercise program or a non-exercise control. The program includes one supervised session per week, two home-based sessions, aerobic warm-ups, strength work with body weight and bands, and a gradual increase in daily activity monitored by steps. Assessments occur at baseline, after the 12-week program, and 12 months later to gauge lasting effects on physical function and cardiorespiratory fitness. The study aims to expand understanding of structured physiotherapy approaches in Fabry disease, which currently have limited evidence.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of Fabry disease
* Age 18 years or older
* Followed at a participating clinical center
* Able to understand the study procedures and provide informed consent
* Clinically stable and medically suitable for exercise testing and participation in the exercise programme

Exclusion Criteria:

* Acute deterioration in health status at the time of enrollment
* Medical contraindication to exercise testing or exercise training
* Severe comorbidity preventing safe participation in the study procedures
* Inability to comply with study procedures or complete follow-up assessments

Where it's running

• General University Hospital
  Prague, Czechia Recruiting

Study contacts

• Study coordinator: Jan Vávra, Masters
• Email: Jan.Vavra2@vfn.cz
• Phone: +420601200272

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lucerastat in untreated adult men with Fabry disease shows how well it works and safety

  This study tests lucerastat to see if it can reduce Gb3 buildup and be safe in untreated adult men with Fabry disease.

  Recruiting Phase 3 Idorsia Pharmaceuticals Ltd. · Birmingham, Alabama and 15 other locations · NCT07778667

• Periodontal Health in Rare Kidney Conditions and Controls

  This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.

  Recruiting Institutul Clinic Fundeni · Bucharest · NCT07575347

• Using advanced heart MRI to improve diagnosis and risk prediction for rare cardiomyopathies

  This project tests whether advanced cardiac MRI techniques can help diagnose and predict future risk for people with rare heart muscle diseases like Danon, Fabry, cardiac amyloidosis, Noonan syndrome, and cardiac sarcoidosis.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing · NCT07336394

• Quality of life for people 65+ with Fabry disease, treated or untreated

  This project will see if starting or continuing Fabry disease treatment changes quality of life over two and five years in people aged 65 and older.

  Recruiting Groupe Hospitalier Diaconesses Croix Saint-Simon · Paris, France · NCT07277361

• Agalsidase alfa for heart inflammation in Fabry disease measured by PET‑CMR

  This study will test whether agalsidase alfa reduces heart inflammation in people with Fabry disease by comparing PET‑CMR scans before and after 12 months of treatment.

  Recruiting Yonsei University · Seoul · NCT07235709

• Agalsidase alfa (Replagal) enzyme replacement for Chinese children and adults with Fabry disease

  This project will test whether agalsidase alfa (Replagal) helps heart and kidney health in Chinese children and adults with Fabry disease.

  Recruiting at 8 sites Takeda · Hefei, Anhui and 17 other locations · NCT07187440

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.